Aberdeen Group plc Increases Stake in Immunovant, Inc. $IMVT

Aberdeen Group plc grew its position in Immunovant, Inc. (NASDAQ:IMVT) by 20.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,184,122 shares of the company’s stock after buying an additional 202,318 shares during the period. Aberdeen Group plc owned approximately 0.68% of Immunovant worth $30,100,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in IMVT. FNY Investment Advisers LLC lifted its position in Immunovant by 100.0% in the 4th quarter. FNY Investment Advisers LLC now owns 4,000 shares of the company’s stock valued at $101,000 after acquiring an additional 2,000 shares in the last quarter. Banque Pictet & Cie SA increased its holdings in shares of Immunovant by 0.9% in the 4th quarter. Banque Pictet & Cie SA now owns 114,881 shares of the company’s stock worth $2,920,000 after purchasing an additional 993 shares in the last quarter. Hennion & Walsh Asset Management Inc. purchased a new position in shares of Immunovant in the fourth quarter worth $1,823,000. Alpine Global Management LLC raised its stake in shares of Immunovant by 4.9% in the third quarter. Alpine Global Management LLC now owns 2,754,731 shares of the company’s stock worth $44,406,000 after purchasing an additional 128,039 shares during the last quarter. Finally, Armistice Capital LLC lifted its holdings in shares of Immunovant by 12.2% during the third quarter. Armistice Capital LLC now owns 5,836,000 shares of the company’s stock valued at $94,076,000 after purchasing an additional 636,000 shares in the last quarter. Institutional investors own 47.08% of the company’s stock.

Immunovant News Summary

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: Management highlights brepocitinib program expansion as a strategic response, signaling a shift of R&D and commercial focus toward the oral JAK/TYK2 asset that could partially offset the batoclimab setback; this gives investors a tangible alternative program to watch for future value creation. Immunovant Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript
• Neutral Sentiment: Company released additional corporate materials/slideshow discussing the pipeline and Phase 3 update; these materials provide management context but don’t replace the clinical outcomes that move valuation. Monitor upcoming investor calls or detailed data disclosures for clarification. Slideshow: Brepocitinib and Batoclimab Phase III Data Update
• Negative Sentiment: Batoclimab failed to meet primary endpoints in Phase 3 TED trials — multiple outlets report the late‑stage miss and its immediate negative market implications; this reduces the expected near‑term revenue runway from that program and increases execution risk. Reuters: Treatment for eye disease fails late‑stage trial
• Negative Sentiment: CEO Eric Venker sold 14,229 shares at an average $24.10 (a ~42% reduction in his holdings), a disclosure that can amplify negative sentiment after the clinical setback; insiders selling after disappointing news may concern some investors. SEC Form 4: Insider Sale

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of Immunovant in a research note on Tuesday, February 10th. The Goldman Sachs Group increased their price objective on shares of Immunovant from $18.00 to $28.00 and gave the company a “neutral” rating in a research report on Monday, December 15th. Guggenheim raised their target price on shares of Immunovant from $41.00 to $44.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunovant in a research report on Friday, January 9th. Finally, Wolfe Research upgraded shares of Immunovant from a “peer perform” rating to an “outperform” rating and set a $50.00 target price for the company in a research note on Tuesday, January 6th. Six research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $32.00.

Immunovant Stock Performance

IMVT opened at $24.50 on Friday. The company’s 50 day moving average is $25.75 and its 200 day moving average is $23.52. The company has a market cap of $4.99 billion, a price-to-earnings ratio of -9.11 and a beta of 0.67. Immunovant, Inc. has a 12-month low of $12.72 and a 12-month high of $29.25.

Immunovant (NASDAQ:IMVT) last announced its earnings results on Friday, February 6th. The company reported ($0.61) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.11. During the same quarter in the previous year, the firm earned ($0.76) EPS. As a group, analysts predict that Immunovant, Inc. will post -2.69 EPS for the current fiscal year.

Insider Transactions at Immunovant

In other Immunovant news, CEO Eric Venker sold 14,229 shares of the business’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $24.10, for a total transaction of $342,918.90. Following the completion of the sale, the chief executive officer owned 19,561 shares of the company’s stock, valued at approximately $471,420.10. The trade was a 42.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Tuyl Christopher Van sold 2,877 shares of the company’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $24.97, for a total value of $71,838.69. Following the completion of the sale, the insider owned 147,053 shares of the company’s stock, valued at approximately $3,671,913.41. The trade was a 1.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 20,286 shares of company stock worth $498,134 in the last three months. Corporate insiders own 1.80% of the company’s stock.

Immunovant Profile

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.